

**CENTER FOR DRUG EVALUATION AND  
RESEARCH**

*APPLICATION NUMBER:*

**210854Orig1s000**

**OFFICER/EMPLOYEE LIST**

MEMORANDUM

DEPARTMENT OF HEALTH AND HUMAN SERVICES  
PUBLIC HEALTH SERVICE  
FOOD AND DRUG ADMINISTRATION  
CENTER FOR DRUG EVALUATION AND RESEARCH

**DATE:** September 10, 2018

**TO:** Administrative file for NDA 210854

**FROM:** Victoria Tyson, Regulatory Health Project Manager  
Division of Antiviral Products, Office of Antimicrobial  
Products

**SUBJECT:** Officer/Employee List for NDA 210854

**APPLICATION/DRUG:** NDA 210854, baloxavir marboxil, XOFLUZA, 20-mg and  
40-mg tablets

The following officers or employees of FDA participated in the decision to approve this application and consented to be identified on this list:

Baylor, Melisse  
Birnkrant, Debra  
Choi, Su-Young  
Diggs, Deacqunita  
ElHagrasy, Arwa  
Englund, Erika  
Fuller, Barbara  
Gershon, Sharon  
Ghantous, Hanan  
Hassan, Hazem  
Ince, William  
Lidoshore, Ruth  
Miller, Stephen  
Murray, Jeffrey  
O'Rear, Julian  
Ossareh, Nima  
Pragani, Rajan  
Redd, Naomi  
Rivera, Luz  
Singer, Mary  
Smith, Fraser  
Thompson, Elizabeth  
Thompson, Susan  
Townsend, Otto  
Tyson, Victoria

Valappil, Thamban  
Wilson, Valerie  
Zhang, Qi  
Zhuang, Luning  
Zvada, Simbarashe